title: Impact of chondroitin sulphate on health utility in patients with knee osteoarthritis: towards economic analysis.
abstract: OBJECTIVE
  The first objective was to assess the effect of the chondroitin 4 and 6 sulphate (CS) on health-related quality of life using utility values in patients with knee osteoarthritis (OA) during a 24-month treatment course. The second objective was, using these data, to conduct economic analyses.
  
  
  METHODS
  Data from the STOPP study was used. This study was a randomised, double-blind, placebo (PL) -controlled trial of 2-year duration. In the STOPP study, authors assessed quality of life using the Western Ontario and McMaster Osteoarthritis Index (WOMAC). WOMAC scores were translated into Health Utility Index (HUI) scores using a specific formula. Incremental cost effectiveness ratio (ICER) was calculated taking into account the cost of CS and its effect on HUI scores, compared to PL.
  
  
  RESULTS
  At baseline, the mean (SD) HUI scores were 0.59 (0.17), and 0.59 (0.18) for the PL and CS groups, respectively (p=0.31 between the two groups). The mean (SD) HUI scores changes from baseline to 6 months were 0.02 (0.02), and 0.05 (0.01) for the PL and CS groups, respectively (p=0.03). After 24 months of follow-up, HUI score increases by 0.04 (0.02) in the PL group and by 0.05 (0.02) in the CS group (p=0.37). Using the price bracket of CS in Europe, ICER assessment always resulted in a cost below €30,000 per QALY gained, after 6, 12 and 24 months of treatment.
  
  
  CONCLUSIONS
  CS treatment increases health utilities in patients with knee OA compared to PL over the first 6 months of treatment. Economic evaluation based on these data suggests that CS treatment could be considered as cost-effective in patients with knee OA up to a period of 24 months. A limitation in this study is the absence of direct utility assessment as well as the absence of effective treatment as comparator.
authors.affiliation: Department of Public Health, Epidemiology and Health Economics, University of Liège, CHU Sart-Tilman, Liège, Belgium. olivier.bruyere@ulg.ac.be
authors.forename: O
authors.initials: O
authors.lastname: Bruyère
authors.forename: S
authors.initials: S
authors.lastname: Scholtissen
authors.forename: A
authors.initials: A
authors.lastname: Neuprez
authors.forename: M
authors.initials: M
authors.lastname: Hiligsmann
authors.forename: A
authors.initials: A
authors.lastname: Toukouki
authors.forename: J Y
authors.initials: JY
authors.lastname: Reginster
mesh_terms: D002809:Chondroitin Sulfates / Q000191:economics* / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D004311:Double-Blind Method; D006296:Health Services / Q000706:statistics & numerical data; D006801:Humans; D008297:Male; D008875:Middle Aged; D009864:Ontario; D020370:Osteoarthritis, Knee / Q000188:drug therapy* / Q000191:economics*; D010147:Pain Measurement; D019057:Quality-Adjusted Life Years
chemical_list: D002809:Chondroitin Sulfates